^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NKX2-1 amplification

    i
    Other names: NKX2-1, NK2 Homeobox 1, Thyroid Transcription Factor 1, Thyroid-Specific Enhancer-Binding Protein, Homeobox Protein NK-2 Homolog A, Thyroid Nuclear Factor 1, NKX2A, TITF1, TTF1, NMTC1
    Entrez ID:
    7080
    Related biomarkers:
    Expression
    Others
    almost3years
    Non-small Cell Lung Carcinoma with Diffuse Co-expression of TTF-1 and p40: Clinicopathologic and Genomic Features of 13 Tumors (USCAP 2022)
    Lung carcinomas with diffuse TTF-1/p40 co-expression represent primarily undifferentiated NSCLCs with frequent basaloid features, but some show morphologic or marker-based evidence of squamous, glandular or dual differentiation. Genomic analysis also supports hybrid features and suggests a distinctly high rate of FGFR1 amplifications. The presence of KRAS G12C mutation is particularly notable given the recent development of targeted therapies for tumors harboring such alterations, which highlights the importance of molecular testing in these tumors.
    Clinical • Tumor Mutational Burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR1 (Fibroblast growth factor receptor 1) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    TP53 mutation • KRAS mutation • TMB-H • KRAS G12C • FGFR1 amplification • KRAS G12 • KRAS amplification • NKX2-1 amplification • NKX2-1 expression